A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

David C Dvorak Invests $5 Million in THINK Surgical

What To Know

  • “Since becoming THINK Surgical’s Chairman, I have gained a much deeper understanding of THINK’s overarching strategy and vision, current product offering and future technology pipeline, as well as the strength of its leadership team,”.
  •   “David’s decades of leadership experience in the orthopedic industry makes his investment a testament to the future growth potential of THINK Surgical.

David C Dvorak investment was completed through Black Lake Expeditions, LLC, an entity for which Mr. Dvorak serves as managing director. Mr. Dvorak became THINK Surgical’s Executive Chairman of the Board last year following an extensive search process.

David C Dvorak had a successful 16-year career at Zimmer Biomet Holdings, Inc. where he most recently held the position of president and chief executive officer for a decade.

“Since becoming THINK Surgical’s Chairman, I have gained a much deeper understanding of THINK’s overarching strategy and vision, current product offering and future technology pipeline, as well as the strength of its leadership team,” said Mr. Dvorak.  “Given his track record of success over decades with Stryker Corporation, including his time as president of the Joint Replacement Division and his experience with Mako robotic-arm technology, Stuart Simpson is uniquely qualified to lead THINK. I am highly confident that under Stuart’s leadership THINK will execute its compelling plans with precision and generate tremendous value for its stakeholders.”

“It is incredibly gratifying and motivating to receive such a significant demonstration of support from David,” said Stuart Simpson, president and chief executive officer of THINK Surgical.  “David’s decades of leadership experience in the orthopedic industry makes his investment a testament to the future growth potential of THINK Surgical.”

About THINK Surgical, Inc.
THINK Surgical, Inc., a privately held U.S.-based medical device and technology company, develops, manufactures, and markets active robotics for orthopedic surgery. The TSolution One® Total Knee Application includes the only commercially available, active robot for total knee arthroplasty (TKA) utilizing an open implant library, supporting a variety of implant options.  The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide.

THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent technology.  Please refer to the instructions for use for the TSolution One Total Knee Application for a complete list of indications, contraindications, warnings, and precautions.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy